Pfizer's Xeljanz Post-Marketing Study Raises Safety Alarms

 
• By Jessica Merrill

A safety study of Pfizer's anchor immunology brand Xeljanz showed higher rates of heart attacks and cancer versus a TNF inhibitor.

flashing light
Pfizer's Xeljanz shows safety issues in a new study • Source: Shutterstock

More from Immunological

More from Therapy Areas